Contrasting Merck & Co., Inc. (NYSE:MRK) and CervoMed (NASDAQ:CRVO)

CervoMed (NASDAQ:CRVO) and Merck & Co., Inc. (NYSE:MRK) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Insider and Institutional Ownership

25.2% of CervoMed shares are held by institutional investors. Comparatively, 76.1% of Merck & Co., Inc. shares are held by institutional investors. 35.8% of CervoMed shares are held by insiders. Comparatively, 0.2% of Merck & Co., Inc. shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares CervoMed and Merck & Co., Inc.”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01 million	11.99	-$26.97 million	($3.22)	-0.99
Merck & Co., Inc.	$65.01 billion	5.41	$18.25 billion	$1.25	114.12

Merck & Co., Inc. has higher revenue and earnings than CervoMed. CervoMed is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for CervoMed and Merck & Co., Inc., as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1	1	4	1	2.71
Merck & Co., Inc.	0	10	17	0	2.63

CervoMed currently has a consensus target price of $21.00, suggesting a potential upside of 560.38%. Merck & Co., Inc. has a consensus target price of $150.32, suggesting a potential upside of 5.37%. Given CervoMed’s stronger consensus rating and higher possible upside, equities analysts clearly believe CervoMed is more favorable than Merck & Co., Inc..

Profitability

This table compares CervoMed and Merck & Co., Inc.’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CervoMed	N/A	-156.02%	-128.34%
Merck & Co., Inc.	4.77%	16.73%	6.13%

Volatility & Risk

CervoMed has a beta of -0.75, suggesting that its share price is 175% less volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500.

Summary

Merck & Co., Inc. beats CervoMed on 10 of the 15 factors compared between the two stocks.

About CervoMed

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

About Merck & Co., Inc.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.